We have now entered 2025 with high energy and a clear focus on driving Aptahem forward. The interest in RNA-related medicines continues to grow and we see increased demand for innovative solutions in this segment. This momentum benefits us and our technology, creating solid conditions for future partnership discussions and strategic meetings.

In addition, Aptahem's election committee has proposed a new addition to the board ahead of the upcoming annual general meeting. Strengthening the board's strategic expertise has been prioritized as the company prepares for the upcoming important development phases in the clinic, capitalization and partnering.

Synopsis for continued clinical development of Apta-1

We are approaching an important milestone in our clinical development. The development of a synopsis for the planned patient studies is entering its final stages, and we have focused on ensuring that the study is optimized for regulatory requirements, clinical implementation and market relevance. We have brought in expertise from several sources to clarify the strategy and optimize the conditions for success.

We look forward to presenting this within short and regard it as a crucial part of our path to clinical phase 2.

Partnering, collaborations and other impressions

In 2025, we have already participated in three important events, two physical and one digital. It is clear that oligonucleotides and RNA-related drugs are increasingly gaining ground in the industry. Companies in the sector are increasingly focused on specific disease indications, which puts us in a unique position to identify the most suitable partners for our technology.

Our strategy is clear: to establish strong partnerships to drive Apta-1 towards commercialization. During these meetings, we have also received valuable feedback on our patient study, which helps us fine-tune our strategy.

In parallel, our scientific collaborations continue towards new interesting results. The two recently published articles confirm Apta-1's broad potential, and the long-term collaboration with Örebro University is now taking the next step with in-depth studies in anti-inflammatory mechanisms. This research strengthens our arguments in our discussions with potential partners and investors.

The collaboration with Japanese e-Projection is progressing, and we await feedback from those who have shown interest. We are aware that business processes in Japan can be lengthy, but we look forward to continued discussions and planned meetings at the Bio Europe conference on 17-19 March.

Upcoming strategic changes

To strengthen the company strategically ahead of the clinical studies, we have proposed changes to the board of directors. Mikael Gustavsson, MD and investor, is proposed as a new board member. His clinical expertise, network and insights into investment strategies will be of great value to Aptahem's continued development. Gustavsson also represents the family office Tuvedalen Limited.

Closing words

The first quarter of 2025 has started at a high pace and with a strong focus on partnerships and the clinical trial synopsis for Phase 2 studies. We are now accelerating further ahead of Bio Europe and other strategic meetings.

The goal is clear: to take Apta-1 to clinical phase 2 and ultimately establish it as a life-saving treatment for patients with serious inflammatory diseases.

Follow us at aptahem.com or our social media, LinkedIn and Facebook.

Wishing you all a nice, warming spring!

Malmö 11 March 2025

Mikael Lindstam
VD, Aptahem AB